NEW YORK – The US Food and Drug Administration has accepted Roche subsidiary Genentech's new drug application for giredestrant in combination with the mTOR inhibitor Afinitor (everolimus) for estrogen ...

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.

The financing will, in part, support an upcoming Phase IIIb trial of its beleaguered stem cell therapy for amyotrophic lateral sclerosis.

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric ...

NEW YORK – Acrivon Therapeutics has received CLIA certification for its laboratory to test patients and develop companion diagnostics for its targeted therapies. The lab will be located at Acrivon's ...

The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.

The nonprofit Finding Hope for Frizzle aims to initiate a clinical trial of the gene therapy for FRRS1L disease in the second half of 2026.

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

NEW YORK – Eli Lilly on Monday said it will share with health authorities results from a Phase III trial of Retevmo (selpercatinib) showing the RET inhibitor improved survival outcomes as an adjuvant ...